SHELTON, CONNECTICUT / ACCESS Newswire / November 10, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today reported that it...
New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual MeetingFollowing the recent presentation...
NEW BRUNSWICK, NEW JERSEY / ACCESS Newswire / November 6, 2025 / E&I Cooperative Services (E&I), the only member-owned, nonprofit...
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate...
One dose elicits robust and long-lasting immune responses in healthy adults in the U.S. and LiberiaKey takeaways:IAVI's Lassa vaccine candidate...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected...
Reports third quarter revenue of $1.0 billion, GAAP net loss of $(0.2) billion and GAAP EPS of $(0.51)Narrows 2025 projected...
LAWRENCEVILLE, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development with...
Business Activity Index at 54.3%; New Orders Index at 56.2%; Employment Index at 48.2%; Supplier Deliveries Index at 50.8% TEMPE,...
Lunai Bioworks Announces Publication of Second-Generation Allogeneic Dendritic Cell Therapy Platform in the journal "Vaccines". LOS ANGELES, Nov. 5, 2025...
OMAHA, Neb., Nov. 5, 2025 /PRNewswire/ -- Tekton Research, a leading multispecialty clinical trial site organization conducting Phase 1-4 trials,...
NV-387 Could be the Answer to the MPox Clade I Rising in the USA, Says Dr. Diwan SHELTON, CONNECTICUT /...
The successful vaccine trials for honeybees, together with recent breakthrough results from clinical trials for disease prevention in shrimp, further...
WAKEFIELD, Mass., Nov. 4, 2025 /PRNewswire/ -- Odyssey, a leading provider of integrated defense capabilities and technologies, announced today it...
Investor event in New York City to provide update on pivotal Phase 3 study of IMNN-001; offering in-person or virtual...
Demonstrated feasibility of effective DNA delivery with Company's xPhore™ nanoparticle technologyDNA delivery technology to be offered as GenePhore™ to biotech...
SHELTON, CONNECTICUT / ACCESS Newswire / November 3, 2025 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader...
CAMBRIDGE, MA / ACCESS Newswire / November 3, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that the first patient has...
COPENHAGEN, Denmark, November 1, 2025 – Bavarian Nordic A/S hereby issues the following clarification regarding the Health Emergency Preparedness and...
Dr. Jay Greenstein, CEO of Embody Health, joins the Disruption/Interruption podcast to discuss how fusing AI with behavioral science and...